Aducanumab tops 2021’s biggest potential launches

Aducanumab tops 2021’s biggest potential launches

Source: 
EP Vantage
snippet: 

The US FDA’s verdict on Biogen’s aducanumab is one of the biggest events on biopharma’s 2021 calendar. And the Alzheimer’s antibody owns another accolade: of the novel projects slated to reach the market this year, aducanumab attracts the sellside's highest revenue forecasts.